Pharvaris N.V.

Contributing Author

Recent Articles by Pharvaris N.V.

Sep-03	Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026 PHVS GlobeNewswire
Aug-12	Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update PHVS +5.93% GlobeNewswire
Aug-06	Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology PHVS GlobeNewswire
Jul-22	Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema PHVS GlobeNewswire
Jul-06	Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks PHVS GlobeNewswire
Jun-15	Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026 PHVS GlobeNewswire
Jun-11	Pharvaris Announces Annual General Meeting of Shareholders PHVS GlobeNewswire
May-29	Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 PHVS GlobeNewswire
May-12	Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update PHVS PHVS +5.41% GlobeNewswire
May-11	Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares PHVS GlobeNewswire
May-08	Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares PHVS GlobeNewswire
Apr-20	Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference PHVS GlobeNewswire
Apr-02	Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update PHVS GlobeNewswire
Mar-20	Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology PHVS GlobeNewswire
Mar-11	Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology PHVS +5.95% GlobeNewswire
Mar-02	Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 PHVS GlobeNewswire
Feb-10	Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting PHVS GlobeNewswire
Jan-12	Pharvaris Outlines 2026 Strategic Priorities PHVS GlobeNewswire
Dec-03	Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks PHVS +21.75% GlobeNewswire
Nov-12	Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update PHVS +7.01% GlobeNewswire
Nov-10	Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting PHVS GlobeNewswire
Oct-23	Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting PHVS GlobeNewswire
Aug-12	Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update PHVS GlobeNewswire
Jul-24	Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares PHVS GlobeNewswire
Jul-22	Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants PHVS -9.86% GlobeNewswire
Jul-22	Pharvaris Announces Proposed Public Offering of Ordinary Shares PHVS PHVS -9.86% GlobeNewswire
Jul-10	Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 PHVS +7.19% GlobeNewswire
Jun-27	Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit PHVS -5.03% GlobeNewswire
Jun-16	Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress PHVS GlobeNewswire
Jun-10	Pharvaris Announces Annual Meeting of Shareholders PHVS GlobeNewswire
Jun-02	Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema PHVS GlobeNewswire
May-19	Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses PHVS GlobeNewswire
May-13	Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update PHVS GlobeNewswire
May-12	Pharvaris to Host a Virtual R&D Call "Deucrictibant: Beyond HAE Type 1/2" on June 4 PHVS GlobeNewswire

Pharvaris N.V.

Recent Articles by Pharvaris N.V.

Upgrade your Finviz experience